Genesco, Inc. (GCO)

NYSEConsumer DiscretionaryApparel - RetailSnapshot 2026-10-23

$36.99-1.07%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Genesco, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q3
Revenue	—	597.7M
EPS	—	0.928
FY 2027 · Annual
Revenue	—	2.38B
EPS	—	2.363
Comparable sales growth	1%–2%non-GAAP	—
FY 2028 · Annual
Revenue	—	2.44B
EPS	—	2.95

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Journeys segment operating income improves to $51.3M by 2026-Q4	A primary condition in Genesco, Inc.'s published investment case. The stated target is >= $51.3M operating income.	Improving	operating income falls below $8.6M in any quarter after 2026-Q4	Operating income: $3.617M FY2027-Q2; GAAP. Published target: >= $51.3M operating income. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Source published Sep 10, 20263,617,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: bbd58c93-a230-4bc6-b11e-89752223a66f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Journeys comparable sales grew mid-single-digits in 2026-Q2 and 2% in 2026-Q3, contributing to net sales growth from $487M to $530M. Management's commentary and sales data show delivering progress on profitability at Journeys. Delivery assessment Oct 24, 2026
Journeys revenue grows to $799.9M by 2026-Q4	A primary condition in Genesco, Inc.'s published investment case. The stated target is >= $799.9M revenue.	Under Pressure	revenue falls below $616.2M in any quarter after 2026-Q4	Revenue: $529.858M FY2027-Q2; GAAP. Published target: >= $799.9M revenue. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Source published Sep 10, 2026529,858,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: bbd58c93-a230-4bc6-b11e-89752223a66f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Journeys comparable sales grew mid-single-digits in 2026-Q2 and 2% in 2026-Q3, contributing to net sales growth from $487M to $530M. Management's commentary and sales data show delivering progress on profitability at Journeys. Delivery assessment Oct 24, 2026
Management stabilizes with new CFO and fewer departures	New CFO hire may stabilize management.	Improving	further key executive departures or activist disruptions	Qualitative: New CFO hired (Jun 2026), CAO promoted (May 2026), no key departures CFO hired, CAO promoted, SVP retiring with transition plan. No negative executive departures or activist threats found. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Schuh gross profit improves to $367.1M by 2026-Q4	Schuh gross profit grew from $289M to $367M.	Improving	gross profit falls below $288.6M in any quarter after 2026-Q4	Gross profit: $272.117M FY2027-Q2; GAAP. Published target: >= $367.1M gross profit. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Source published Sep 10, 2026272,117,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: bbd58c93-a230-4bc6-b11e-89752223a66f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. Adjusted gross margin improved 140 basis points to 47.2% in 2026-Q3 from 45.8% in 2025-Q3, driven by less promotional activity and higher full-price selling at Schuh. Management's focus on margin improvement at Schuh is reflected in the margin gains. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-01-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	Unavailable	Unavailable	3 / 3
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	Unavailable	Unavailable	3 / 3
2026-08-06	Unavailable	Unavailable	3 / 3
2026-08-07	Unavailable	Unavailable	3 / 3
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	4 / 4
2026-08-14	Unavailable	Unavailable	3 / 3
2026-08-15	Unavailable	Unavailable	3 / 3
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	3 / 3
2026-08-21	Unavailable	Unavailable	3 / 3
2026-08-22	Unavailable	Unavailable	3 / 3
2026-08-23	Unavailable	Unavailable	3 / 3
2026-08-24	Unavailable	Unavailable	3 / 3
2026-08-25	Unavailable	Unavailable	3 / 3
2026-08-26	Unavailable	Unavailable	3 / 3
2026-08-27	Unavailable	Unavailable	3 / 3
2026-08-28	Unavailable	Unavailable	3 / 3
2026-08-29	Unavailable	Unavailable	3 / 3
2026-08-30	Unavailable	Unavailable	3 / 3
2026-08-31	Unavailable	Unavailable	3 / 3
2026-09-01	Unavailable	Unavailable	3 / 3
2026-09-02	Unavailable	Unavailable	3 / 3
2026-09-03	Unavailable	Unavailable	3 / 3
2026-09-04	Unavailable	Unavailable	2 / 2
2026-09-05	Unavailable	Unavailable	3 / 3
2026-09-06	Unavailable	Unavailable	3 / 3
2026-09-07	Unavailable	Unavailable	3 / 3
2026-09-08	Unavailable	Unavailable	3 / 3
2026-09-09	Unavailable	Unavailable	3 / 3
2026-09-10	Unavailable	Unavailable	3 / 3
2026-09-11	Unavailable	Unavailable	3 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	3 / 3
2026-09-20	Unavailable	Unavailable	3 / 3
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	3 / 3
2026-09-24	Unavailable	Unavailable	3 / 3
2026-09-25	Unavailable	Unavailable	3 / 3
2026-09-26	Unavailable	Unavailable	3 / 3
2026-09-27	Unavailable	Unavailable	3 / 3
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	3
2026-06-01	1	3
2026-07-01	1	3
2026-08-01	1	3
2026-09-01	1	3
2026-10-01	1	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Journeys segment operating income improves to $51.3M by 2026-Q4Operating income: $3.617M
Journeys revenue grows to $799.9M by 2026-Q4Published status: Under Pressure
Schuh gross profit improves to $367.1M by 2026-Q4Gross profit: $272.117M

Next proof point

Dec 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-38.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Genesco, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk operating improvement story, not a proven durable compounder: earnings quality and the value factor are both marked loss-making. The thesis has improved recently, but remains under watch because financial performance is still below its industry cohort.

What's priced into Genesco, Inc.

GCO trades at a 1.63 times premium versus peers, with a modest expectations gap of 0.3 and no flagged valuation-fragility concerns. The evidence points to a valuation that may depend on a re-rating, but it does not establish that the premium is justified while the company remains loss-making.

What the fundamentals likely do

Near term, recent results show progress: Journeys comparable sales grew, Schuh’s adjusted gross margin improved, and management reported initial cost savings progress. Momentum improved and the latest earnings event was positive, though CEO and president transitions add execution uncertainty; the estimated near-term miss probability is 26%, with a quiet watch tier.

What Genesco, Inc. hinges on

Over the next one to three years, the thesis depends on sustained progress in Journeys profitability, Schuh margins, and the cost savings plan through Fiscal 2029. A guidance cut after the recent increase would weaken management credibility, while continued strength or weakness at TJX, ROST, and BURL could shape the sector backdrop.